{"id":802683,"date":"2026-05-17T10:58:20","date_gmt":"2026-05-17T10:58:20","guid":{"rendered":"https:\/\/www.europesays.com\/us\/802683\/"},"modified":"2026-05-17T10:58:20","modified_gmt":"2026-05-17T10:58:20","slug":"could-eli-lillys-next-weight-loss-drug-waylay-wegovy-and-even-zap-zepbound","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/802683\/","title":{"rendered":"Could Eli Lilly’s Next Weight Loss Drug Waylay Wegovy — and Even Zap Zepbound?"},"content":{"rendered":"\n

After losing its market edge to Eli Lilly<\/strong> (NYSE: LLY) despite its first-mover advantage in weight-loss drugs, Novo Nordisk<\/strong> is trying to close the gap. The maker of the semaglutide GLP-1 weight loss drug Wegovy launched a pill-based version at the start of this year. Still, much suggests that Eli Lilly could still stay on top.<\/p>\n

Last quarter, sales of its anti-obesity drug, Zepbound were up 80% from a year ago. The upcoming launch of newer, more powerful products could further cement its dominance. This will likely drive continued strong performance for the popular pharmaceutical stock<\/a>.<\/p>\n\n\n

Will AI create the world’s first trillionaire?<\/strong> Our team just released a report on a little-known company, called an “Indispensable Monopoly,” providing the critical technology Nvidia and Intel both need. <\/p>\n

Continue \u00bb<\/strong><\/a> <\/p>\n<\/td>\n<\/tr>\n

\"A Image source: Getty Images. Eli Lilly and its gambit to stay on top of the GLP-1 heap <\/p>\n

By launching a pill-based version of Wegovy, Novo Nordisk is capitalizing on patients’ preference for oral treatments over injectables.<\/p>\n

However, Eli Lilly launched its own weight loss pill, orforglipron, marketed as Foundayo, in April. And the company has another drug candidate, retatrutide, that targets GLP-1 and GIP receptors, as well as glucagon receptors.<\/p>\n

That’s significant given Eli Lilly’s other therapies. A key reason for the success of its Zepbound drug is its status as a “dual agonist.” Wegovy targets only GLP-1 receptors, whereas tirzepatide (aka Zebound) targets both GLP-1 and GIP receptors, leading to greater overall weight loss. With retatrutide, Eli Lilly aims to bring to market a “triple agonist,” targeting GLP-1 and GIP receptors, as well as glucagon receptors. Meanwhile, Novo Nordisk is still developing its own “dual agonist” product.<\/p>\n

What this means for the stock <\/p>\n

In March, Eli Lilly unveiled promising phase 3 clinical trial data for retatrutide. In this trial, the drug resulted in significant reductions in A1C and weight loss among participants.<\/p>\n

Retatrutide remains months, if not a year, away from launch, but bullishness about its high commercial potential could help keep Eli Lilly at elevated prices. Trading for over $1,000 per share, the stock may seem pricey at over 26 times forward earnings. However, if Eli Lilly’s follow-up products help it maintain its edge, the market will continue to consider it one of the top GLP-1 stocks<\/a>, enabling it to sustain a premium valuation.<\/p>\n

Should you buy stock in Eli Lilly right now? <\/p>\n

Before you buy stock in Eli Lilly, consider this:<\/p>\n

The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a><\/strong> for investors to buy now\u2026 and Eli Lilly wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n

Consider when Netflix<\/strong> made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $469,293<\/strong>!* Or when Nvidia<\/strong> made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,381,332<\/strong>!*<\/p>\n

Now, it\u2019s worth noting\u00a0Stock Advisor\u2019s total average return is 993% \u2014 a market-crushing outperformance compared to 207% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.<\/strong><\/p>\n

See the 10 stocks \u00bb<\/strong><\/a><\/p>\n

*Stock Advisor returns as of May 17, 2026. <\/p>\n

Thomas Niel<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy<\/a>.<\/p>\n

Could Eli Lilly’s Next Weight Loss Drug Waylay Wegovy — and Even Zap Zepbound?<\/a> was originally published by The Motley Fool<\/p>\n","protected":false},"excerpt":{"rendered":"After losing its market edge to Eli Lilly (NYSE: LLY) despite its first-mover advantage in weight-loss drugs, Novo…\n","protected":false},"author":3,"featured_media":802684,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[25996,210,1060,9412,67,132,68,428],"class_list":{"0":"post-802683","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-eli-lilly","9":"tag-health","10":"tag-medication","11":"tag-novo-nordisk","12":"tag-united-states","13":"tag-unitedstates","14":"tag-us","15":"tag-weight-loss"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/802683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=802683"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/802683\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/802684"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=802683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=802683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=802683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}